Carcinoma, Transitional Cell: all 725 studies

Page 3 of 8. Open to participants first (201), then studies with results posted, then the rest; newest registration first within each.

• Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial CarcinomaRecruitingNCT02969083Phase 2
• A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerCompletedNCT06331299Phase 3Results posted
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursTerminatedNCT05714553Phase 1/2Results posted
• A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has SpreadCompletedNCT05431777Results posted
• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2Results posted
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerActive, not recruitingNCT05243550Phase 3Results posted
• Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedNCT05136898Phase 3Results posted
• Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial CancerTerminatedNCT04936230Phase 2Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabTerminatedNCT04887831Phase 2Results posted
• Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)TerminatedNCT04871529Phase 2Results posted
• Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04856189Phase 1/2Results posted
• A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMACompletedNCT04822350Results posted
• A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerTerminatedNCT04688931Phase 3Results posted
• Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results posted
• Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial CarcinomaCompletedNCT04602078Phase 2Results posted
• An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedNCT04586244Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial CarcinomaTerminatedNCT04501094Phase 2Results posted
• Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder CancerCompletedNCT04496219Phase 2Results posted
• Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesCompletedNCT04383938Phase 1/2Results posted
• Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial CarcinomaTerminatedNCT04322643Phase 2Results posted
• Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerTerminatedNCT04228042Phase 1/2Results posted
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3Results posted
• Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedNCT04045613Phase 1/2Results posted
• Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder CancerTerminatedNCT04039867Phase 2Results posted
• 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical CystectomyCompletedNCT04018053Early Phase 1Results posted
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 2Results posted
• Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder CancerTerminatedNCT03912818Phase 2Results posted
• Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)CompletedNCT03898180Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results posted
• Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaTerminatedNCT03737123Phase 2Results posted
• Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With PembrolizumabCompletedNCT03674567Phase 1/2Results posted
• Trial of Mitomycin C During Nephroureterectomy for Urothelial CarcinomaCompletedNCT03658304Phase 2Results posted
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer SurvivorsTerminatedNCT03641287Not applicableResults posted
• Evaluation of NanoDoce® in Participants With Urothelial CarcinomaCompletedNCT03636256Phase 1/2Results posted
• A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03606174Phase 2Results posted
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted
• A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerCompletedNCT03558503Phase 2Results posted
• Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial CancerCompletedNCT03557918Phase 2Results posted
• Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted
• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results posted
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaCompletedNCT03513952Phase 2Results posted
• INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaCompletedNCT03502785Phase 1/2Results posted
• Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial CarcinomaTerminatedNCT03486197Phase 2Results posted
• Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial CarcinomaCompletedNCT03473756Phase 1Results posted
• A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerActive, not recruitingNCT03473743Phase 1/2Results posted
• A Study of E7130 in Participants With Solid TumorsTerminatedNCT03444701Phase 1Results posted
• Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for ChemoCompletedNCT03421652Phase 2Results posted
• Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03410693Phase 2/3Results posted
• Rucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT03397394Phase 2Results posted
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaCompletedNCT03374488Phase 3Results posted
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results posted
• Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial CarcinomaTerminatedNCT03287050Phase 2Results posted
• Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerTerminatedNCT03272217Phase 2Results posted
• Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial CancerCompletedNCT03240016Phase 2Results posted
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03219333Phase 2Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsActive, not recruitingNCT03047213Phase 2Results posted
• A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based TherapyTerminatedNCT03029832Phase 2Results posted
• Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1TerminatedNCT03007719Phase 2Results posted
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsCompletedNCT02983045Phase 1/2Results posted
• Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02923739Phase 2Results posted
• Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the BladderTerminatedNCT02901548Phase 2Results posted
• Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial CarcinomaTerminatedNCT02887248Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)CompletedNCT02872714Phase 2Results posted
• Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)CompletedNCT02853305Phase 3Results posted
• Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerCompletedNCT02844816Phase 2Results posted
• Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerCompletedNCT02808143Phase 1Results posted
• Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT02807636Phase 3Results posted
• The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC StudyCompletedNCT02793128Phase 3Results posted
• Genomic Based Assignment of Therapy in Advanced Urothelial CarcinomaCompletedNCT02788201Phase 2Results posted
• Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT02769962Phase 1/2Results posted
• Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial CancerTerminatedNCT02693717Phase 2Results posted
• Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial CancerCompletedNCT02581982Phase 2Results posted
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid TumorsCompletedNCT02573259Phase 1Results posted
• Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial CancerCompletedNCT02567409Phase 2Results posted
• Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder CancerCompletedNCT02500121Phase 2Results posted
• Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
• Neoadjuvant Atezolizumab in Localized Bladder CancerCompletedNCT02451423Phase 2Results posted
• A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical ResectionTerminatedNCT02450331Phase 3Results posted
• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results posted
• A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial CancerCompletedNCT02426125Phase 3Results posted
• Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract CancerCompletedNCT02412670Phase 2Results posted
• Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder CancerCompletedNCT02351739Phase 2Results posted
• Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyTerminatedNCT02334527Phase 2Results posted
• Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid TumorsCompletedNCT02318329Phase 1Results posted
• Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder CancerCompletedNCT02300610Phase 1Results posted
• Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and SarcomasTerminatedNCT02192541Phase 1Results posted
• Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by SurgeryCompletedNCT02178241Phase 2Results posted
• Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCGCompletedNCT02015104Phase 2Results posted
• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder CancerCompletedNCT01780545Phase 2Results posted
• Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expressionTerminatedNCT01732107Phase 2Results posted
• Cabozantinib for Advanced Urothelial CancerCompletedNCT01688999Phase 2Results posted
• Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)TerminatedNCT01663285Phase 2Results posted
• Dalantercept in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01642082Phase 2Results posted
• Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based ChemotherapyTerminatedNCT01622660Phase 2Results posted
• Bristol Bladder TrialCompletedNCT01616875Phase 2Results posted
• Buparlisib in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT01551030Phase 2Results posted
• First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial CarcinomaCompletedNCT01524991Phase 2Results posted
• Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based ChemotherapyCompletedNCT01437488Phase 2Results posted

← Carcinoma, Transitional Cell overview